DULUTH, MN (KDAL) – Essentia Health has joined a nationwide study to evaluate re-purposed medications as a COVID treatment.
The study is to evaluate whether medications now used for other conditions might treat mild to moderate COVID cases.
The ACTIV-6 study is open to anyone 30 and older and the double blind study is hoping to enroll about 15 thousand participants across the country.
The medications now a part of the ACTIV-6 study are Fluticasone, an inhaled steroid now prescribed for asthma and COPD, Fluvoxamine often used for depression and Ivermectin used to treat parasitic infections.
Essentia Health will enroll and monitor the patient’s progress through the study and a 90 day follow-up period.
Comments